Sponsor hub

New York State Psychiatric Institute clinical trial failures

Review 56 stopped clinical trials from New York State Psychiatric Institute, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 1 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials56
Likely biological signals1
Shown below56

Dominant stop reasons

OPERATIONAL
35
OTHER/UNKNOWN
19
EFFICACY/FUTILITY
1
REGULATORY
1

Notable sponsors

New York State Psychiatric Institute
56

Related phases

Phase II
17
Phase IV
16
Phase I
12
Unknown
5
Phase III
4

Crawlable stopped-trial records

Open Explore

Showing up to 56 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04640636: IM Ketamine vs Midazolam for Suicidal ER Patients

Phase IV Depression, Unipolar trial by New York State Psychiatric Institute. Stop reason: OTHER/UNKNOWN.

The U.S. Department of Health and Human Services (HHS) Office of Human Research Protections (OHRP) issued an FWA restriction on NYSPI research that also included a pause of human subjects research as of June 23, 2023.

NCT05046353: D-serine AudRem: R33 Phase

Phase I Schizophrenia trial by New York State Psychiatric Institute. Stop reason: OPERATIONAL.

U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. NKI site is open for enrollment.

NCT05401227: Glutamatergic Mechanisms: Aim2

Phase I Healthy trial by New York State Psychiatric Institute. Stop reason: OPERATIONAL.

U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will resume recruitment after OHRP has approved the resumption of research.

NCT04786548: Neuroinflammation in Patients With OCD

Phase II Obsessive-Compulsive Disorder trial by New York State Psychiatric Institute. Stop reason: OTHER/UNKNOWN.

The NYSPI site is currently paused and has been paused since an institutional pause on human subjects research on March 14, 2024.

NCT03766971: Influence of Tobacco Use on Cannabis Use

Phase II Cannabis Use trial by New York State Psychiatric Institute. Stop reason: OTHER/UNKNOWN.

In response to quality assurance and compliance concerns, OHRP issued an FWA restriction on NYSPI research that included a pause of human research as of June 23, 2023.

NCT05114460: Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal

Phase II Opioid Overdose trial by New York State Psychiatric Institute. Stop reason: OPERATIONAL.

The U.S. Department of Health and Human Services Office of Human Research Protections issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. Recruitment for this trial will not reopen.

NCT04322305: Pregabalin Trial for the Treatment of Alcohol Use Disorder

Phase II Alcohol Use Disorder trial by New York State Psychiatric Institute. Stop reason: OPERATIONAL.

U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will resume recruitment after OHRP has approved the resumption of research.

NCT05427981: Anti-suicidal Effects of Buprenorphine In Depressed Individuals

Phase III Suicidal Ideation trial by New York State Psychiatric Institute. Stop reason: OPERATIONAL.

U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will not resume recruitment after the resumption of research.